Divi’s Labs Grows By Almost Half
Company Sees ‘Minimal Impact’ From COVID-19
Despite having ongoing expansion activities held back due to the impact of COVID-19, India’s Divi’s Laboratories has been able to enjoy “near normal operations” during its financial first quarter, reporting 47% growth, compared to the prior year period.
You may also be interested in...
As the global generics industry had predicted, the unexpected growth seen in the first quarter of 2020 due to forward buying caused by COVID-19 levelled off in the second quarter. However, a few companies managed to report a “mixed” second quarter or a positive first half for 2020, even after experiencing challenges, such as operational interruptions, posed by the pandemic.
A modest rise in Divi's Labs' custom synthesis business offset strong growth in nutraceuticals, while a gross margin contraction resulted in the firm's net profit falling.
Divi’s Laboratories says it is investing Rs12.0 billion (US$163 million) in two of its sites in India “in order to cater to the increasing opportunities in generic and big pharmaceutical business”.